LegoChem Biosciences, Inc.
KOSDAQ 141080.KQ
LegoChem Biosciences, Inc. EBITDA for the year ending December 31, 2023: USD -54.82 M
-
LegoChem Biosciences, Inc. EBITDA for the year ending December 31, 2022 was USD -34.26 M, a -133.58% change year over year.
-
LegoChem Biosciences, Inc. EBITDA for the year ending December 31, 2021 was USD -14.67 M, a 40.30% change year over year.
-
LegoChem Biosciences, Inc. EBITDA for the year ending December 31, 2020 was USD -24.57 M, a -267.79% change year over year.
-
LegoChem Biosciences, Inc. EBITDA for the year ending December 31, 2019 was USD 14.64 M, a 169.65% change year over year.
| Date | EBITDA | Net Income | EPS (Diluted) | Shares (Diluted, Weighted) |
|---|
| CEO | Mr. Yong Zu Kim Ph.D. |
| IPO Date | May 10, 2013 |
| Location | |
| Headquarters | 10, Gukjegwahak 10-ro |
| Employees | 157 |
| Sector | Health Care |
| Industries | |
LegoChem Biosciences, Inc. a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, and oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It offers its products in the forms of tablets and capsules. The Company also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. LegoChem Biosciences, Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email